Quest to Develop NGS-based Dx on Life Tech and Illumina Sequencing Systems | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics has struck multi-year agreements with both Illumina and Life Technologies to use their respective sequencing technologies for clinical testing, the firms said today.

Under two separate agreements, Quest will have the right to develop and offer molecular laboratory-developed tests using Illumina's MiSeq and Life Tech's Ion Torrent platforms and the respective related reagents for clinicians and clinical trials performed by its pharmaceutical and biotechnology clients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.